The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.
Showing results 31 - 40 of 46
BioPIC CAB for PrEP Study Compendium
This compendium provides detail on planned and ongoing studies related to landscaping, product introduction, introduction studies, and implementation research for Cabotegravir for PrEP and is a companion to the Implementation Study Tracker. If you would like to add your study to the compendium, please contact Catherine Verde Hashim.
Implementation Study Tracker
This study tracker, produced under the BioPIC platform, reflects all currently known activities relating to landscaping, product introduction, introduction studies, and implementation research for new biomedical PrEP options, including cabotegravir for PrEP and the dapivirine vaginal ring. To update or add any activities missing from the tracker, please contact Catherine Verde Hashim to ensure they…
The Years Ahead in Biomedical HIV Prevention Research
This graphic shows the updated status of large-scale prevention trials through 2024.
Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach
These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic recommendations across different ages, populations and settings, bringing together all relevant WHO guidance on HIV produced since 2016. It serves as an update to the previous edition of the consolidated guidelines on HIV.
Normative Guidance/Policies, Service Delivery
The Future of ARV-Based Prevention and More
The pipeline of non-vaccine HIV prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable antiretrovirals and more. Also pictured are the range of multipurpose prevention technologies in development that aim to reduce the risk of HIV and STIs and/or provide effective contraception for women.
Stakeholder Conversations to Inform Delivery of New HIV Prevention Methods in South Africa
Little is known about what is needed for health care providers to ensure adequate counseling on method choice, referral mechanisms, and supportive follow-up with regards to multiple biomedical HIV prevention methods. The goal of these conversations with stakeholders in South Africa was to gain input on implementation considerations from provider and potential end-user perspectives, as…
Stakeholder conversations to inform delivery of new HIV prevention methods in Zimbabwe
Little is known about what is needed for health care providers to ensure adequate counseling on method choice, referral mechanisms, and supportive follow-up with regards to multiple biomedical HIV prevention methods. The goal of these conversations with stakeholders in Zimbabwe was to gain input on implementation considerations from provider and potential end-user perspectives, as well…
Modelling Impact of Injectable Cabotegravir for PrEP on Drug Resistance
An important consideration in the scale-up of injectable cabotegravir (CAB) for PrEP is the potential for development of Integrase Strand Transfer Inhibitor (INSTI) resistance. To help stakeholders understand this issue further, Professor Andrew Phillips from University College London shared the results of an exercise modelling the impact of the introduction of CAB for PrEP on…
Financing & Costing, Testing
HIV Testing and Injectable Cabotegravir (CAB for PrEP) Introduction: What are the implications for HIV prevention scale-up and the HIV response?
One challenge which has emerged with the introduction of CAB for PrEP is the risk of Integrase Strand Transfer Inhibitor (INSTI) resistance amongst people who acquire HIV while taking CAB as prescribed. To address emerging evidence around testing algorithms and INSTI resistance in CAB users, AVAC and WHO convened a think tank with program implementers,…